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SURVEILLANCE OF MULTIDRUG-RESISTANT UROPATHOGENIC ESCHERICHIA
COLI IN HOSPITALIZED PATIENTS AND COMMUNITY SETTINGS IN THE SOUTH
OF LEBANON
Abstract
Urinary Tract Infection (UTI) is one of the common infectious diseases in both hospitals as well as
community settings; they are recognized to be among the most serious worldwide bacterial infections
impacting 150 million people globally every year. The purpose of this study was to assess the changing
antibiotics resistance profile for uropathogenic Escherichia coli isolated from community and hospital
setting over a period of time (2018–2019) with a special emphasis on ESBL/MDR producing Escherichia
coli. A descriptive retrospective study was conducted among patients with uropathogenic Escherichia
coli from both community and hospital settings in south Lebanon. Out of 863 patients with positive
uropathogenic Escherichia coli, 451 (52.25 %) comes from the community while 412 (47.74 %) came from
the hospital settings. Almost 60.83 % are not Extended Spectrum Beta-Lactamases (ESBL), 31.4 % ESBL,
and 7.76 % Multiple drug resistance (MDR). The majority of urinary tract infections are related to the
female population (78.21 %). The most vulnerable age for both gender to develop UTI belong to elderly
population (>64 years) which account 37.19 % of all isolates. Statistically, we observed a high resistance
rate toward all antibiotics using in the treatment of urinary tract infections such as Cefixime (45.30 %),
Sulfamethoxazole (44.95 %), Ciprofloxacin (38.23 %) and Augmentin (38.93 %). A statistically significant
association was observed between risk factors for hospitalized patients and all age categories with (P <
0.05). Susceptibility profiles are critical to be evaluated in countries such as Lebanon where excessive use
of antibiotics is observed at all levels. Therefore, this finding is useful for the determination of appropriate
antimicrobial treatment in UTI patients that are caused by Escherichia coli and to follow the antimicrobial
stewardship program to reduce the rate of resistance toward antibiotics.
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1. INTRODUCTION
Urinary Tract Infections (UTIs) constitute the main cause of morbidity and mortality
worldwide (Foxman, 2010).
The key cause of UTIs is reported to be Escherichia coli (E. coli)
(Farajnia et al., 2009), and the uropathogenic E. coli (UPEC), a subset of pathogenic extra-intestinal
E. coli (ExPEC) group, is associated with causing more than 80% of all UTIs (Ronald, 2002). It has
been guesstimate that 150 million UTIs occur per year globally (Stamm & Norrby, 2001). UTI
happens eight times more often in females than in males, and about 50-60% of women report at least
one UTI in their lifespan (Foxman et al., 2000; Rahn, 2008; Al-Badr and Al-Shaikh, 2013). In the
US, UTIs are accountable for >7 million physician visits yearly and 15% of all community-prescribed
antibiotics, with similar statistics in some European countries (Bonkat et al., 2017). E. coli causes the
majority of UTIs and pyelonephritis, where the host vaginal or fecal microbiota is the most common
source for these strains—termed Uropathogenic E. coli—although UPECs are not necessarily the
predominant clones from these reservoirs.
However, there is a frightening level of antimicrobial resistance developing in UTI
pathogens as a consequence of random and global use of antibiotics. Bacteria producing extendedspectrum beta-lactamases (ESBLs), exhibiting resistance to most antibiotics except for the
carbapenem group, are steadily increasing in the population (Bonkat et al., 2017; Oteo et al., 2010).
ESBLs are enzymes that break down commonly used antibiotics, such as penicillins and
cephalosporins, making them ineffective. ESBL-producing Enterobacteriaceae often cause infections
in otherwise healthy people. Over the past twenty years, the antimicrobial resistance of ExPEC to
first-line antibiotics, such as amoxicillin and ciprofloxacin has escalated markedly (Foxman, 2010).
Additionally, an increased extended-spectrum β-lactamase (ESBL) carriage has been announced
among ExPEC strains (Pitout et al., 2005b). As reported in 2008, E. coli sequence type 131 (E. coli
ST131) was described among ESBL-producing E. coli in many continents throughout the world, and
it has distributed to become the preponderant ExPEC clone that drives multidrug resistance (MDR)
universally (Nicolas-Chanoine et al., 2014). MDR is when a single bacterium is resistant to more than
one antibiotic it is said to be multidrug-resistant. Antimicrobial resistance is currently one of the main
issues in public health (Cassini et al., 2019). The prevalence of multidrug-resistant (MDR) bacteria
has risen significantly in recent decades, and the World Health Organization (WHO) has incorporated
antimicrobial resistance in its list of 10 world threats to public health. Infections by MDR organisms
are especially important in health care settings. However, they have also increased in frequency in
community settings (Kaarme et al., 2018). These infections have a poorer prognosis because of the
delay in the initiation of suitable antibiotic therapy and the need for alternative antibiotics, which are
usually less effective and are less secure (Chiotos et al., 2016; Folgori et al.,2017).
The increase of antibiotic resistance and development of multi-drug resistant (MDR)
pathogens in the course of UTI is correlated with high rates of inadequate antibiotic empirical
therapies prescribed without checking for antibiotic susceptibility testing and finally result in an
ineffective UTI treatment (Adamus-Białek 2018). As a consequence, surveillance and antimicrobial
stewardship programs have been directed to optimize the prevention and control of infections by
lowering antibiotic resistance rates in hospitals (CDC, 2013).
According to a study previously carried out in Beirut (Daoud & Afif, 2011), E. coli was
the most recurrent isolate (60.64% of the total isolates) and an increase in the production of ESBL
was noticed between the years 2000 and 2009 (2.3% to 16.8%). Unfortunately, very limited data
concerning UTIs is obtainable from other regions of the country. The purpose of this study was to
assess the changing antibiotics resistance profile for uropathogenic Escherichia coli isolated from
community and hospital setting over a period of time (2018–2019) with a special emphasis on
ESBL/MDR producing Escherichia coli. The findings of this study will redound to the benefit of the
Lebanese healthcare society by showing the real fact of the antibiotics' resistance in the hospital and
community setting and make it the first step for improvement later through the infection control
program.
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2. METHODOLOGY
The aim of this study was to assess the changing antibiotics resistance profile for
uropathogenic Escherichia coli isolated from community and hospital setting over a period of time
(2018–2019) with a special emphasis on ESBL/MDR producing Escherichia coli. A descriptive crosssectional research design was adopted. This study was conducted in laboratory department of one
hospital in South, Lebanon. An official permission to conduct this study was obtained from the
responsible authorities referred to institutional review board (IRB) at Beirut Arab University, and the
ethical committee at the relevant clinical site after explaining the aim of the study, where the
anonymity and confidentiality of the data have been guaranteed to be maintained. All Patients (863)
who have positive UPEC belong to any age group and gender were included in the study. Patient that
have urinary tract infection caused by other bacteria than Escherichia coli were excluded. Hospital
based UTI was defined to be prevalent after 48 hours of admission. Data was collected retrospectively
for the two years 2018/2019. Nine hundred and thirteen cases were recorded to be eligible to be
included in the research, however the researchers were able to access the files of 863 patients therefore
a rate of 94.52%. The Statistical Package for Social Science (Corp, 2013) was used to analyze the
data. Descriptive statistics were utilized to describe the characteristics of the patients that suffer from
positive UPEC. The inferential statistics were used to test the relationship between variables.

3. RESULTS
3.1. Socio-Demographic Characteristics Of Patient With Positive UPEC
The study included eight hundred thirty-six patients (N= 863), where 675 (78.21 %)
of them were females while 188 (21.78 %) of them were males. With regard to the age categories
of patients, a total of 321 (37.19 %) samples were collected from the elderly, 305 (35.34 %)
samples belong to adults population, and 237 (27.46 %) were obtained from children. In addition,
412 (47.74 %) are hospitalized admitted patient (inpatient) while 451 (52.25 %) came from the
community setting (outpatient). The demographics characteristics of the patient are shown in
table 1
Table 1: Sociodemographic characteristics
Variables
Gender
Age

Setting

Category
Male
Female
<18
18-64
>64
Inpatient
Outpatient

Total n (%)
188(21.78)
675(78.21)
237(27.46)
305(35.34)
321(37.19)
412(47.74)
451(52.25)

Moreover, with respect to setting or location, inpatients females are at higher risk for the
development of UTIs than males respectively (295, 71.60 %; VS 117, 28.39 %).Also, outpatient
is higher in female than male respectively (380, 84.25 %; VS 71, 15.74 %).On the other hand, a
total of 197 (83.12 %) were collected from female children, 251 (82.29 %) collected from adult
females, and 227 (70.71 %) collected from an elderly female. While, 40 samples (16.87 %)
collected from male children, 54 (17.70 %) from adult males and 94 (29.28 %) from the elderly
males (Table 2).
Table 2: Distribution of UPEC by age category and setting with respect to gender
Gender
Setting
Inpatient
Outpatient
Age
<18
18-64
>64

https://digitalcommons.bau.edu.lb/hwbjournal/vol3/iss1/5

Male

Female

117(28.39)
71(15.47)

295(71.60)
380(84.25)

40(16.87)
54(17.70)
94(29.28)

197(83.12)
251(82.29)
227(70.71)
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3.2. Prevalence Of ESBL and MDR Production Among UPEC
A descriptive analysis was carried out to assess the prevalence of MDR and ESBL
production among UPEC. From 863 patients with positive uropathogenic Escherichia coli, we
have 525(60.83 %) samples are non ESBL, 271(31.4 %) ESBL & 67(7.76 %) sample are MDR.
Also, the most associated group for both ESBL and MDR are from the female population (200
samples, 73.8 % VS; 47 samples, 70.14 %) compared to male (71 samples, 26.19%, VS; 20
samples, 29.85 %) respectively with P-value = 0.011 which is significantly associated with a P
value less than 0.05. On the other hand, ESBL and MDR are significantly higher in the
hospitalized patient (inpatient) (156 samples, 37.86%; 43 samples, 10.43%) compared to
outpatient (115 samples, 25.49%; 24 samples, 5.32%) respectively with P value=0.000* (Table
3).
Table3.Prevalence of ESBL and MDR producing among UPEC
Variables

Category

ESBL

MDR

Gender

M
F
>18
18-64
>64
Inpatient
Outpatient

71(26.19)
200(73.8)
75(27.67)
78(28.78)
118(43.54)
156(57.56)
115(42.43)

20(29.85)
47(70.14)
20(29.85)
18(26.86)
29(43.28)
43(64.17)
24(35.82)

Age

Setting

3.3. Antimicrobial Profile
A descriptive analysis was also carried out to determine antimicrobial susceptibility
for UPEC strains. The results of antibiotic susceptibility showed that the highest resistance rate
was against amoxicillin (73.58%) followed by cefuroxime (55.38%), tetracycline (50.28%),
Cefixime (45.3 %), Sulfamethoxazole (44.95 %) and Norfloxacin (40.55 %). On the other hand,
the highest susceptibility was toward Colistin (99.07 %), Imipenem (99.18 %), Meropenem
(98.95 %), Nitrofurantoin (98.95 %), Fosfomycin (98.72 %), Pipracillintazobactam (91.42 %),
Amikacin (91.19 %) and Gentamicin (66.85 %) (Table 4).
Table 4: Antimicrobial susceptibility for UPEC strains
Antibiotics

Resistance

Intermediate

Susceptible

Amoxicillin
Augmentin

636(73.69)
336(38.93)

69(7.99)
239(4.51)

158(18.30)
28(33.37)

Cefixime

391(45.30)

30(3.47)

441(51.10)

Cefotaxime
Cefoxitine

339(39.28)
89(10.31)

5(0.57)
82(9.50)

519(60.13)
692(80.18)

Ceftriaxone

339(39.28)

2(0.23)

522(60.48)

Ceftazidime
Cefuroxime

342(39.26)
478(55.38)

7(0.81)
4(0.46)

514(59.55)
381(44.14)

Ciprofloxacin

330(38.23)

40(4.63)

493(57.12)

Norfloxacin
Levofloxacin

350(40.55)
324(37.54)

38(4.40)
30(3.47)

475(55.04)
509(58.98)

Amikacin

32(3.70)

44(5.09)

787(91.19)

Gentamicin

187(21.66)

99(11.47)

577(66.85)

Nitrofurantoin
Fosfomycin

9(1.04)
22(2.54)

0(0)
0(0)

854(98.95)
852(98.72)

PipracillinTazobactam

33(3.82)

41(4.75)

789(91.42)

Colistin
Imipenem

8(0.92)
6(0.69)

0(0)
1(0.11)

855(99.07)
856(99.18)

Meropenem

8(0.92)

1(0.11)

854(98.95)

Sulfamethoxazole
Tetracycline

388(44.95)
434(50.28)

2(0.23)
19(2.2)

473(54.80)
410(47.5)
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3.4. Comparison of Antimicrobial Resistance Pattern Among UPEC for Year 2018 and
2019
Descriptive analysis was made to make a comparison between the years 2018 and
2019. For the year 2018, we have 384 patients with uropathogenic Escherichia coli while in 2019
we have 479 patients with uropathogenic Escherichia Coli. Based on the resistance profile for the
year 2018 and 2019, we see an increase resistance toward all antibiotics that’s used to treat urinary
tract infection such as Cefixime (41.66 %, VS 48.22 %) ,Augmentin (36.45 % ,VS 40.9 %),
Sulfamethoxazole (42.18 %, VS 47.18 %), Gentamicin (16.92 %, VS 25.05 %), Nitrofurantoin
(0.78 %, VS 1.25 %), Fosfomycin (2.08 %, VS 2.92 )and Levofloxacin (36.97 %, VS 37.99 %)
respectively (Table 5).
Table 5: Comparison of Antimicrobial profile for the years 2018 and 2019
2018

2019

Antibiotics

Resistance

Intermediate

Susceptible

Resistance

Intermediate

Susceptible

Amoxicillin

278(72.39)

31(8.07)

75(19.53)

357(74.53)

38(7.93)

83(17.32)

Augmentin

140(36.45)

107(27.86)

137(35.67)

196(40.90)

132(27.55)

151(31.52)

Cefixime

160(41.66)

12(3.12)

211(54.94)

231(48.22)

18(3.75)

230(48.01)

Cefotaxime

141(36.71)

1(0.26)

242(63.02)

198(41.33)

4(0.83)

277(57.82)

Cefoxitine

38(9.89)

32(8.33)

314(81.77)

51(10.64)

50(10.43)

378(78.91)

Ceftriaxone

140(36.45)

4(1.04)

240(62.5)

199(41.54)

2(0.41)

278(58.03)

Ceftazidime

142(36.97)

3(0.78)

239(62.23)

200(41.75)

4(0.83)

275(57.41)

Cefuroxime

169(51.04)

2(0.52)

186(49.21)

282(58.87)

2(0.41)

195(40.70)

Ciprofloxacin

147(38.28)

18(4.68)

219(57.03)

182(37.99)

22(4.59)

274(57.20)

Norfloxacin

162(42.18)

15(3.90)

207(53.90)

188(39.24)

23(4.80)

268(55.94)

Levofloxacin

142(36.97)

14(3.64)

228(59.37)

182(37.99)

16(3.34)

281(58.66)

Amikacin

10(2.60)

13(3.38)

361(94.01)

22(4.59)

31(6.47)

526(88.93)

Gentamicin

65(16.92)

34(8.85)

285(74.21)

120(25.05)

65(13.56)

292(60.96)

Nitrofurantoin

3(0.78)

0(0)

381(99.21)

6(1.25)

0(0)

473(98.74)

Fosfomycin

8(2.08)

0(0)

376(97.91)

14(2.92)

0(0)

464(96.86)

PipracillinTazobactam

13(3.38)

23(5.98)

348(90.62)

20(4.17)

18(3.75)

439(91.64)

Colistin

0(0)

0(0)

384(100)

8(1.67)

0(0)

471(98.32)

Imipenem

0(0)

0(0)

384(100)

6(1.25)

1(0.20)

472(98.53)

Meropenem

0(0)

0(0)

284(100)

8(1.67)

1(0.20)

470(98.12)

Sulfamethoxazole

162(42.18)

2(0.52)

220(57.29)

226(47.18)

0(0)

253(52.81)

Tetracycline

196(51.04)

16(4.16)

172(44.79)

238(49.68)

3(0.62)

238(49.68)

3.5. Susceptibility Profile For ESBL And NON-ESBL Escherichia Coli Isolated From
Urine
A descriptive analysis was also carried out to determine the susceptibility profile of
ESBL Escherichia coli isolated from the urinary tract. Among all antibiotics tested in this study
for extended-spectrum beta-lactamase (ESBL), Carbapenem, Nitrofurantoin, and Fosfomycin
was the most active against Escherichia coli isolates, also 90.77 % to piperacillin-tazobactam,
83.02 % to Amikacin and 53.87 % to gentamicin. Out of 271 ESBL producing Escherichia .coli
isolates, 98.52% were resistant to amoxicillin, 66.05 % to Norfloxacin, 64.20% to Ciprofloxacin,
63.09% to Levofloxacin, 62.36% to Augmentin, and 34.68% to Gentamicin (Table 6).
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Table 6: Antimicrobial profile for ESBL producing UPEC
Antibiotics

Resistance

Intermediate

Susceptible

Amoxicillin

267(98.52)

0(0)

4(1.47)

Augmentin

169(62.36)

94(34.68)

8(2.95)

Cefixime

267(98.52)

1(0.36)

3(1.10)

Cefotaxime

266(98.15)

1(0.36)

4(1.47)

Cefoxitine

2(0.73)

42(15.49)

227(8.11)

Ceftriaxone

267(98.52)

0(0)

4(1.47)

Ceftazidime

267(98.52)

0(0)

4(1.47)

Cefuroxime

268(98.89)

0(0)

3(1.10)

Ciprofloxacin

174(64.20)

10(3.69)

87(32.10)

Norfloxacin

179(66.05)

11(4.05)

81(29.88)

Levofloxacin

171(63.09)

10(3.69)

90(33.21)

Amikacin

17(6.27)

29(10.70)

225(83.02)

Gentamicin

94(34.68)

31(11.43)

146(53.87)

Nitrofurantoin

2(0.73)

0(0)

269(99.26)

Fosfomycin

9(3.32)

0(0)

262(96.67)

PipracillinTazobactam

6(2.21)

19(17.01)

246(90.77)

Colistin

1(0.36)

0(0)

270(99.63)

Imipenem

1(0.36)

0(0)

270(99.63)

Meropenem

1(0.36)

0(0)

270(99.63)

Sulfamethoxazole

153(56.45)

1(0.36)

106(39.11)

Tetracycline

170(62.73)

8(2.95)

93(34.31)

3.6. Distribution Of Antimicrobial Profile For MDR Escherichia Coli Isolates From
Urine
A descriptive analysis was also carried out to determine the Distribution of Multi-drug
resistant (MDR) Escherichia coli isolates among urine. The results show that Multidrug-resistant
isolates were resistant 100% to Cephalosporin’s & amoxicillin, 77.61% to Trimethoprimsulfamethoxazole, 71.64% to Norfloxacin, and 67.16 % to Ciprofloxacin & levofloxacin.
Moreover, the distribution of ciprofloxacin (231 samples, 70.21 %) and levofloxacin (227
samples, 70.06 %) resistance was significantly higher among female than male gender with Pvalue =0.000*. Also, UPEC isolates from hospital-acquired infection was associated with
Ceftazidime (P=0.000*) and MDR phenotype in a hospitalized patient more than in the
community-acquired infection respectively (64.17% VS 35.82%, P= 0.000*) (Table 7).
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Table 7: Antimicrobial profile for MDR Escherichia coli isolated from urine
Antibiotics

Resistance

Intermediate

Susceptible

Amoxicillin
Augmentin

67(100)
67(100)

0(0)
0(0)

0(0)
0(0)

Cefixime

66(98.50)

0(0)

1(0.19)

Cefotaxime

66(98.50)

0(0)

1(0.19)

Cefoxitine

63(94.02)

3(0.57)

1(0.19)

Ceftriaxone

66(98.50)

0(0)

1(0.19)

Ceftazidime

64(95.52)

2(0.38)

1(0.19)

Cefuroxime

66(98.50)

0(0)

1(0.19)

Ciprofloxacin

45(67.16)

5(0.95)

17(3.23)

Norfloxacin

48(71.64)

2(0.38)

17(3.23)

Levofloxacin

45(67.16)

3(0.57)

19(11.23)

Amikacin

4(5.97)

4(5.97)

59(5.90)

Gentamicin

30(44.77)

6(1.14)

31(5.90)

Nitrofurantoin

3(4.47)

0(0)

64(12.19)

Fosfomycin

2(2.98)

0(0)

65(12.38)

PipracillinTazobactam

19(28.35)

11(2.09)

37(7.04)

Colistin

4(5.97)

0(0)

63(12)
63(12)

Imipenem

3(4.47)

1(0.19)

Meropenem

4(5.97)

0(0)

63(12)

Sulfamethoxazole

52(77.61)

0(0)

15(2.85)

Tetracycline

45(67.16)

2(0.38)

20(3.80)

3.7. Results of Chi-square
A Chi-Square test was carried out to determine if there is an association between age
and gender on one hand and the location on the other. During the study, females (675 samples,
78.21 %) were the most affected group of patients with P-value <0.05 as compared to males (188
samples, 21.78 %). Moreover, most of the urinary tract infection was detected in a community
setting (451 samples, 52.25 %) while 412 were obtained from hospital-acquired infection (47.74
%). Also, females of age group 18-64 years (251 samples, 37.18 %) are more prone to develop
urinary tract infections than males (54 samples, 28.72 %) with highly significant P value (< 0.05).
However, females were correlated with community-acquired urinary tract infection of both age
groups (<18 & 18-64) and with hospital-acquired infection of age group (>64) with P-value <
0.05. Therefore, the results showed that there is a significant relationship between the age and
gender where a significant-value of p = 0.000* was recorded. In addition, another highly
significant association was noted between the age and location of where a p-value of p =
0.000*was recorded (Table 8).
Table 8: Results of association between age with gender and setting
Age

All patient

Male

Female

N=863

N=188

N=675

<18

237(27.46)

40(21.27)

197(29.18)

18-64

305(35.34)

54(28.72)

>64

321(37.19)

94(50)

HAI

CAI

N=412

N=451

0.000

73(17.71)

164(36.36)

0.000

251(37.18)

0.000

100(24.27)

205(45.45)

0.000

227(33.62)

0.000

239(58)

82(18.18)

0.000
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Another chi-Square test was carried out to determine if there is an association between
antibiotic resistance and gender on one hand and the location on the other. High frequency of
resistance was observed toward Amoxicillin (73.69 %), cefuroxime (55.38 %), tetracycline
(50.98 %), cefixime (45.30 %), TM/SMX (44.95 %), and norfloxacin (40.55 %). From twentyone different antibiotics tested, highly susceptible isolates were toward imipenem, meropenem,
colistin, nitrofurantoin, fosfomycin, and amikacin with low resistance rate respectively (0.69 %,
0.92 %, 0.92 %, 1.04 %, 2.54 %, and 3.7 %). Among 863 we have 67 isolates were related to
multidrug-resistant organisms MDR (7.76 %). MDR organisms were highly resistant toward
amoxicillin and cephalosporin, TM/SMX (77.61 %), tetracycline (67.67 %) and gentamicin
(44.77 %). Moreover, the fluoroquinolone-resistant strain showed MDR. And the percentage for
resistance toward these families was 71.64 % to norfloxacin 67.16 % to ciprofloxacin and, 67.16
% to levofloxacin. Moreover, the distribution of quinolones family that includes (ciprofloxacin,
norfloxacin, and levofloxacin) resistance was significantly higher among male than female
gender (52.12 %, 53.19 %, 51.59 %, P=0.000*, VS 34.37 %, 37.03%, 33.62%) and also, these
quinolones antibiotics are higher in hospitalized patient than in community-acquired infection
respectively (53.88 %, 54.61 %, 53.15 %, P=0.000* VS, 23.94 %, 27.71 %, 23.28 %). Therefore,
the results showed that there is significant association between gender and antibiotics include:
cefotaxime (p=0.009), cefoxitine (0.000*), ceftriaxone (p=0.012), ceftazidime (p=0.012) and
quinolones family with p value =0.000*, amikacin (p=0.047) and gentamicin (p= 0.000*). Also,
the results of this analysis showed that there is a significant relationship between location and
antibiotics that include: Augmentin (p=0.004), cefixime (0.000*), cefotaxime (p=0.000*),
cefoxitine (p=0.002), ceftriaxone, ceftazidime, cefuroxime, tetracycline ciprofloxacin,
norfloxacin and levofloxacin with p value =0.000*, gentamicin (p=.008) (Table 9).
Table 9: Results of association between antibiotics with gender and setting
Antibiotics

All patient

MDR

Male

Female

N=863

N=67

N=188

N=675

Amoxicillin

636 (73.69)

67(100)

144(76.59)

492(72.88)

Augmentin

336(38.93)

67(100)

76(40.42)

Cefixime

391(45.30)

66(98.5)

Cefotaxime

339(39.28)

Cefoxitine

89(10.31)

Ceftriaxone

339(39.28)

Ceftazidime

P

CAI

HAI

P

N=451

N=412

0.58

321(71.17)

315(76.45)

0.091

260(38.51)

0.278

155(34.36)

181(43.93)

0.004

101(53.72)

290(42.96)

0.068

172(37.13)

219(53.15)

0.000

66(98.5)

91(48.40)

248(36.74)

0.009

139(30.82)

200(48.54)

0.000

63(94.02)

26(13.82)

63(9.33)

0.000

35(7.76)

54(13.10)

0.002

66(98.5)

91(48.40)

248(36.74)

0.012

139(30.82)

200(48.54)

0.000

342(39.26)

64(95.52)

92(48.93)

250(37.03)

0.012

139(30.82)

203(49.27)

0.000

Cefuroxime

478(55.38)

66(98.5)

116(61.70)

362(53.62)

0.095

223(49.44)

255(61.89)

0.000

Ciprofloxacin

330(38.23)

45(67.16)

98(52.12)

232(34.37)

0.000

108(23.94)

222(53.88)

0.000

Norfloxacin

350(40.55)

48(71.64)

100(53.19)

250(37.03)

0.000

125(27.71)

225(54.61)

0.000

Levofloxacin

324(37.54)

45(67.16)

97(51.59)

227(33.62)

0.000

105(23.28)

219(53.15)

0.000

Amikacin

32(3.70)

4(5.97)

8(4.25)

24(3.55)

0.047

15(3.32)

17(4.12)

0.369

Gentamicin

187(21.66)

30(44.77)

71(37.76)

116(17.18)

0.000

79(17.51)

108(26.21)

0.008

Nitrofurantoin

9(1.04)

3(4.47)

2(1.06)

7(1.03)

0.974

7(1.55)

2(0.48)

0.123

Fosfomycin

22(2.54)

2(2.98)

2(1.06)

20(2.96)

0.144

11(2.43)

11(2.66)

0.830

PipracillinTazobactam

33(3.82)

19(28.35)

8(4.25)

25(3.70)

0.673

13(2.88)

20(4.85)

0.279

Colistin

8(0.92)

4(5.97)

1(0.53)

7(1.03)

0.523

4(0.88)

4(0.97)

0.898

Imipenem

6(0.69)

3(4.47)

1(0.53)

5(0.74)

0.830

4(0.88)

2(0.48)

0.451

Meropenem

8(0.92)

4(5.97)

2(1.06)

6(0.88)

0.849

4(0.88)

4(0.97)

0.573

Sulfamethoxazole

388(44.95)

52(77.61)

85(45.21)

303(40.88)

0.756

183(40.57)

205(49.75)

0.025

Tetracycline

434(50.28)

45(67.16)

95(50.53)

339(50.22)

0.815

196(43.45)

238(57.76)

0.000
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3.8. Risk factor for UPEC in Hospitalized Patient
Descriptive and inferential analysis chi-square was also carried out to determine the risk
factors for acquiring uropathogenic Escherichia coli in hospitalized patients according to gender
and age group. Out of N=412 hospitalized patients (inpatient), where 294 (71.35 %) of them were
female while, 118 (28.64 %) of them belong to a male. With regard to gender, females are more
prone to develop urinary tract infection than males as see in table menopausal female (204
samples, 69.38 %, P=0.000*) which is significantly associated with urinary tract infection. Also,
another risk factor such as diabetic patient was higher in female than male (34.01 %, VS 16.10
%) with p value=0.000* also the previous hospitalization is significantly associated with UTI
development especially in the female population than male respectively (64.28 %, VS 50.84 %)
with P-value =0.012. While there is no association between gender and previous antibiotics use
with (P Value=0.861). On the other hand, with regard to the age category, there is a significant
association between older age category (>64 years) and menopause (166 samples, 70.33 %),
diabetic (98 samples, 41.52 %), previous hospitalization (166 samples, 70.33 %) & previous
antibiotics (169 samples, 71.61 %) however, all of them with P-value =0.000* which is less than
0.05 and therefore it’s strongly associated (Table 10).
Table10: Risk factor for UPEC in hospitalized patient
Category
Gender
Male
Female
Age
<18
18-64
>64

Menopause

P

Diabetic

P

0(0)
204(69.38)

0.000

19(16.10)
100(34.01)

0.000

60(50.84)
189(64.28)

0.000

2(2.73)
19(18.44)
98(41.52)

0.000

32(43.83)
51(49.51)
166(7.33)

0(0)
38(36.89)
166(70.33)

Previous
hospitalization

P

Previous
antibiotics

P

0.012

74(62.71)
187(63.6)

0.865

0.000

34(46.57)
58(56.31)
169(71.61)

0.000

4. DISCUSSION
This chapter provides a general discussion of the study findings, which compares our results
to that of various other studies that have to investigate to evaluate UPEC. However, in south Lebanon,
there are no studies on microbiological surveillance of multidrug-resistant UPEC at hospitals and
community settings or related topics. Because urinary tract infection is one of the most common
medical problems affecting the population. This retrospective study aim to describe the prevalence of
uropathogenic Escherichia coli (N=863 isolates) from the community (451 isolates ) and hospitalacquired (412 isolates) urinary tract infections and their antibiotics resistance profile between the
years 2018 and 2019 at the capital hospital ( Alnajdi hospital) in the Nabatieh area at the south of
Lebanon.
In the present study, 863 patients with positive uropathogenic Escherichia coli were
reported, 675 cases (78.21%) were female, while 188 cases (21.78%) were male (P<0.05). Gender
and urinary tract infections were found to have a major correlation. This result is consistent with
Mahesh et al (Mahesh et al., 2010), demonstrating that female urinary tract infection was higher than
males (65 %, 35% respectively). With regard to the age category, the female population was higher
than the male population throughout all age groups, studies have demonstrated that the higher
prevalence of urinary tract infection in females can be attributed to many factors, such as the
anatomical factor suggesting that urethra in females is shorter than in males and closer to anus,
increasing the probability that Escherichia coli bacteria can be easily translatable to the bladder
(Ghanbari et al. 2017; Tabasi et al., 2015) Poor hygiene and sexual activity as well as contraception
use (John et al., 2016). This finding is consistent with previous studies in Lebanon and other countries
that in our study, the prevalence of urinary infection toward females was higher than those of males
within all age groups (Daoud, 2011; Tajbakhsh et al., 2015; Ghanbari et al., 2017; Tabasi et al., 2015).
In addition, UTIs in our sample are more prevalent throughout the older age group (> 64 years), which
is 37.19 %; increasing risk of prostate problem prevalence in males and diabetes mellitus are willing
to increase the incidence of UTI in elderly patients (Mahesh et al., 2010).
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The diagnosis and treatment of diseases in this age group (>64 years) have become more
important because of the growing elderly population worldwide. UTI is a major cause of mortality
and morbidity in older patients. Urinary tract infection is amongst the most considerable causes of
sepsis in elderly patients, with a mortality rate of 33 percent associated with urosepsis. (Gbinigie et
al., 2018). Visits to the outpatient clinic by the elderly population due to Urinary tract infection were
noted to be three times greater than those in the younger population (Cortes-Penfield et al., 2017).
This was typically associated with age-related bladder malfunction, urethral catheterization, and
blood vessel obstruction related to benign prostatic hyperplasia, especially in males. Additionally,
due to repeated antibiotic therapies, resistance to antibiotics is higher in older patients along with
young patients (Gbinigie et al., 018).
The study revealed the prevalence of UPEC's broad spectrum beta-lactamase phenotype
was (31.4 %) but was low in this study for multidrug-resistant (8 %) like other Mexican studies
recording (16.4 percent) of MDR strain (Ochoa et al., 2016). While (Paniagua –Contreras et al.,
2017)'s research has shown 97 percent of multidrug-resistant strains. The burden of ESBL in
community-acquired infections is also increasing (Rodríguez-Bano et al., 2008) noted that older age,
men, DM existence, and fluoroquinolone utilization over the last two months are risk factors in
community-acquired ESBL-producing E. coli infection. In response, serious adverse effects such as
fluoroquinolone-induced QT prolongation, delirium, and seizures were recorded by the United States
Food and Drug Administration in May 2016 (Gbinigie et al., 2018). Therefore the use of
fluoroquinolone must be restricted in patients who are at high risk. The involvement of ESBL in this
research was greater than in other studies (Coskun USS, Coskun G, 2015; Asgin & Satilmis, 2019;
Duman et al., 2010). This may be attributable to our patient group comprising of elderly patients and
fluoroquinolone being unnecessary prescribed.
In this study, all species of Escherichia coli (N=863) were resistant to amoxicillin (73.58
percent) suggesting a careful use of these antibiotics to treat urinary tract infection. Resistant
Escherichia coli to the family penicillin community was on a higher side in different parts of the
world, and it is growing day by day (Olowe et al., 2007). Resistance to the combination amoxicillinCA (Augmentin 38.93 percent) was also high like other studies that posted similar findings (Drawz
& Bonomo, 2010). The degree of resistance in E.coli strains to amoxicillin-clavulanic acid in elderly
patients was 39.58 %. In agreement with the research by Ulug et al. (Ulug &Gul, 2012), this incidence
was stated to be 33 percent in elderly patients. In addition, the resistance rates to third-generation
cephalosporins include cefixime in E. coli strains were 37%, high resistance to cefixime may be
explained by the fact that our research group composed of elderly patients. In general, antibiotic
resistance in the elderly population is perceived to be higher relative to that in the young. It could be
due to excessive antibiotic (Palacios-Ceña et al., 2017).
For this research project, the rate of TMP-SMX resistance in E. coli was 35%. Likewise,
high resistance rates were recorded in the Brazilian (35 percent) (Marques, 2012) and the US (60
percent) studies (Das et al., 2009). In contrast, Fagan et al.'s analysis (Fagan et al., 2015) (Norway)
noticed resistance levels to be 24 percent. However, Over 44 percent of isolates displayed TM-SMX
resistance, which is prescribed as the first option for UTI treatment (Ali et al., 2014). Similar results
have been recorded in recent studies (Pniagua-Contreras et al., 2017). In particular, TM-SMX's
resistance rate increased from 2018 (42.18%) to 2019 (47.18%) in my study so, the rise in resistance
indicates that great caution should be exercised when deciding to use this antibiotic.
The rise in fluoroquinolone usage (Ciprofloxacin, Levofloxacin & Norfloxacin), increases
the probability of global resistance to these antibiotics in uropathogens (Fasugba et al., 2015). With
respect to this phenomenon, the increase in resistance of fluoroquinolones among UPEC isolates are
now leading to demands to counter their use as agents of the first choice (Stewardson et al., 2018) in
agreement with Hoban et al.(2012). In this study, more than 37% of UPEC isolates were resistant to
ciprofloxacin and levofloxacin antibiotics. Also, the rate of antimicrobial resistance towards these
antibiotics was higher for males than for female patients (Linhares et al., 2017). In agreement with
(Ali et al., 2019; Wagenlehner et al., 2007), we noticed older men (> 64 years) had increased risks of
FQ-resistant (fluoroquinolones) UTIs. Interestingly, fluoroquinolones are commonly used in male
patients for treating UTI. Thus, it may be more difficult for male infections to eliminate due to the
higher level of antibiotic resistance found in male-isolated strains, which can lead to persistent
infection. Such findings were similar to earlier papers (Tabasi et al., 2015; Ali et al., 2016; Ibrahim
et al., 2012).
Published by Digital Commons @ BAU, 2020
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Moreover, the prevalence of ciprofloxacin resistance in E. coli strains was 42%. We agree that
the misuse of fluoroquinolones in the treatment of infections other than UTI in our hospital has
resulted in high resistance to fluoroquinolone. The levels of resistance to ciprofloxacin in a multicenter study performed on elderly patients, Escherichia Coli strains were estimated to be 30% in
Canada and 44% in the US (Lob et al., 2016). Sanchez et al. (Sanchez et al., 2013) documented
resistance rates of 11% in adults, and 30% in aging patients while, Fagan et al. (Fagan et al., 2015)
recorded relatively low resistance levels toward UPEC which is 8 %. Furthermore, research carried
out in Spain has shown that fluoroquinolone-resistant for E.coli is prevalent in older age groups
(Nicolle et al., 2016). Also, a history of hospitalization and the use of fluoroquinolones are
independent risk factors for developing this resistance toward antibiotics (Das et al., 2009; Smithson
et al., 2012).On the other hand, Ciprofloxacin and co-trimoxazole resistance associations with past
UTI diagnosis are compatible with existing literature (Denheijer et al., 2013; Briongos-figuero et al.,
2012), and the relationship between ciprofloxacin resistance and hospitalization could be due to a
significantly increased prevalence of resistance in hospital settings (Fasugba et al., 2015).
The usage of nitrofurantoin is prevalent in the treatment of ESBL-positive UPEC.
However, in uncomplicated UTI, nitrofurantoin is prescribed only (Cortes-Penfield et al., 2017;
Nicolle, 2016). The rate of nitrofurantoin resistance for E.coli in the current study was 1.04 %.
However, Nitrofurantoin resistance levels were stated to be 2 percent in Fagan et al. (Norway) study
(Fagan et al., 2015) and 7 percent in Das et al. (USA) study (Das et al., 2009). Generally, the vast
majority of isolates remained susceptible to fosfomycin and nitrofurantoin, in terms of empirical
therapy. Both of these are recommended antibiotics in international recommendations for
uncomplicated UTIs (over amoxicillin-clavulanate, which is assumed to have weaker effectiveness,
more adverse effects, and a wider cover spectrum (Gupta et al., 2010).
It is well established that patterns of susceptibility can differ from country to country
geographic regions and can change with time (Ali et al., 2016). As a result, UPEC's rate of resistance
to commonly used antimicrobials has grown over the years. As we see in this study resistance rate
from the year 2018 to 2019 toward trimethoprim-sulfamethoxazole increases from (42.18 % to
47.18%), cefixime (41.66 % to 48.22 %) and for augmentin (36.45 % to 40.90%) (Gupta et al., 2001).
On the other hand, antimicrobial resistance among UPEC was growing in both community and
hospital settings (Bonadio et al., 2001). However, carbapenems stay as the last line of treatment
against infection caused by varieties of drug resistance that are strongly against the hydrolysis of betalactamase. The reason for the increasing antibiotic resistance identified in this study may, therefore,
be linked to the inappropriate use of antibiotics (Frère & Rigali, 2016). The other is prescribing
inaccurate and irrational antibiotics. Thus, over-treatment with antibiotics can lead to antibiotic
resistance and increase the persistence of extended-spectrum beta-lactamase and thus increase the rate
of multidrug-resistant organisms.
Our study results indicate that in postmenopausal women with positive uropathogenic
Escherichia coli and type 2 diabetes UTIs are typical and occur in every 1 in 3 patients. In our
research, the prevalence of UTI observed in postmenopausal women with type 2 diabetes is equivalent
to a study done by (Al-Rubeaan et al., 2013) or higher than that recently reported studies (Hirji et
al., 2012). In addition to the range of postmenopausal status, the number of variations in the
comorbidities of patients and other variables, such as age, may explain the discrepancy. Postmenopausal loss of estrogen is related to deregulate immunity mechanisms that are required to protect
against E. coli adhesion to cells in the vagina. The lack of estrogen also makes the walls thinner and
reduces the ability of the urinary tract to resist bacteria. As for diabetes itself, the clinical postmenopausal status can contribute to other UTI-related problems, such as neuropathy leading to
incomplete voiding of the clinical bladder and glycosuria (Funfstuck et al., 2012). Based on the results
reported from this study antimicrobial stewardship program needs to be enforced to control antibiotic
use and specifically decrease antibiotic resistance. Similarly, understanding of patterns of bacterial
resistance in Escherichia coli is very relevant in the selection of empirical antimicrobial therapy to
reduce urinary tract infection incidence.
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5. CONCLUSION
A- The study revealed that uropathogenic Escherichia coli ( UPEC) is the most common infectious
disease in both the hospital and community settings and its affect a member of patients with
different risk factors.
B- The study detects that higher rate of resistance toward commonly used antibiotics family that
includes Penicillin, Cephalosporin’s, Fluor quinolones, and Trimethoprim-sulfamethoxazole.
These increase the development of AMR that has faced physicians with limited options to choose
the correct antibiotics to treat the infections caused by MDR organisms.
C- The study also suggests that judicious use of antibiotics, proper culture, and drug susceptibility
monitoring and regulation of empiric antibiotics by culture and sensitivity is global conflictridden in order to stop the growth of drug resistance, especially MDR, in order to limit
complication associates with ESBL/MDR organisms related to urinary tract infection.

6. ACKNOWLEDGEMENTS
I take time to acknowledge the people in my life who have been supportive during this journey.
First, all praise and thanks to Allah, for giving me the power, guidance, strength, and patience to
complete this work.I want to express my deepest gratitude to my supervisor Dr. Mirna Fawaz and to
professor Dr.Ali smaha, M.D, medical science and Dr.Ahmad Tassi for continuous guidance, detailed
comments, encouragement, insightful suggestions, time, and support. I must also thank the
administration of Beirut Arab University and the hospital (ALnajdi hospital) who shared in the study
for their approval to conduct this research and special thanks to Dr. Nadia Fayad the director of the
laboratory department and Miss. Fawazieh Najem, a supervisor at Alnajdi hospital for showing their
encouragement toward conducting this research study. My continuous source of strength has been
my family and friends. I am thankful for their faith and love, which inspired my ambition and passion
to complete this journey.

REFERENCES
−
−
−
−
−
−
−
−

−

−

Adamus-Białek, W., Baraniak, A., Wawszczak, M., Głuszek, S., Gad, B., Wróbel, K., &
Parniewski, P. (2018). The genetic background of antibiotic resistance among clinical
uropathogenic Escherichia coli strains. Molecular Biology Reports, 45(5), 1055-1065.
Al-Badr, A., & Al-Shaikh, G. (2013). Recurrent urinary tract infections management in women:
A review. Sultan Qaboos University Medical Journal, 13(3), 359.
Ali, I., Kumar, N., Ahmed, S., & Dasti, J. I. (2014). Antibiotic resistance in uropathogenic E. coli
strains isolated from non-hospitalized patients in Pakistan. Journal of Clinical and Diagnostic
Research: JCDR, 8(9), DC01.
Al-Rubeaan, K. A., Moharram, O., Al-Naqeb, D., Hassan, A., & Rafiullah, M. R. M. (2013).
Prevalence of urinary tract infection and risk factors among Saudi patients with diabetes. World
Journal of Urology, 31(3), 573-578.
Asgin, N., & Satilmis, Ş. (2019). Which antibiotics should we prefer empirical treatment of urinary
tract infections in elderly patients.Journal of Surgery and Medicine, 3(12), 856-860.
Bonadio, M., Meini, M., Spitaleri, P., & Gigli, C. (2001). Current microbiological and clinical
aspects of urinary tract infections. European Urology, 40(4), 439-445.
Bonkat, G., Pickard, R., Bartoletti, R., Bruyère, F., Geerlings, S. E., Wagenlehner, F., & Wullt, B.
(2017). EAU guidelines on urological infections. European Association of Urology, 22-26.
Briongos‐Figuero, L. S., Gómez‐Traveso, T., Bachiller‐Luque, P., Domínguez‐Gil González, M.,
Gómez‐Nieto, A., Palacios‐Martín, T., & Pérez‐Castrillón, J. L. (2012). Epidemiology, risk factors
and comorbidity for urinary tract infections caused by extended‐spectrum beta‐lactamase (ESBL)‐
producing enterobacteria. International Journal of Clinical Practice, 66(9), 891-896.
Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., &
Ouakrim, D. A. (2019). Attributable deaths and disability-adjusted life-years caused by infections
with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A
population-level modelling analysis. The Lancet Infectious Diseases, 19(1), 56-66.
Centres for Disease Control and Prevention (US). (2013). Antibiotic resistance threats in the
United States, 2013. Centres for Disease Control and Prevention, US Department of Health and
Human Services.

Published by Digital Commons @ BAU, 2020

11

BAU Journal - Health and Wellbeing, Vol. 3, Iss. 1 [2020], Art. 5

−
−
−
−
−
−
−
−
−
−

−
−
−
−
−
−
−
−
−
−
−

Chiotos, K., Han, J. H., & Tamma, P. D. (2016). Carbapenem-resistant Enterobacteriaceae
infections in children. Current Infectious Disease Reports, 18(1), 2.
Corp, I. B. M. (2013). IBM SPSS statistics for windows, version 22.0. Armonk, NY: IBM Corp.
Cortes-Penfield, N. W., Trautner, B. W., & Jump, R. L. (2017). Urinary tract infection and
asymptomatic bacteriuria in older adults. Infectious Disease Clinics, 31(4), 673-688.
Coşkun, U. S. Ş., & Coşkun, G. (2015). Bir devlet hastanesinde poliklinik hastalarına ait idrar
örneklerindenizole edilen genişlemiş spektrumlu Beta-Laktamaz pozitif escherichia coli suşlarının
prevalans ve antibiyotik duyarlılıklarının belirlenmesi. Kocatepe Tıp Dergisi, 16(1), 25-30.
Daoud, Z., & Afif, C. (2011). Escherichia coli isolated from urinary tract infections of Lebanese
patients between 2000 and 2009: epidemiology and profiles of resistance. Chemotherapy Research
and Practice, 2011.
Das, R., Perrelli, E., Towle, V., Van Ness, P. H., & Juthani-Mehta, M. (2009). Antimicrobial
susceptibility of bacteria isolated from urine samples obtained from nursing home residents.
Infection Control & Hospital Epidemiology, 30(11), 1116-1119.
Den Heijer, C. D., Penders, J., Donker, G. A., Bruggeman, C. A., & Stobberingh, E. E. (2013).
The importance of gender-stratified antibiotic resistance surveillance of unselected uropathogens:
A Dutch Nationwide Extramural Surveillance study. PloS One, 8(3).
Drawz, S. M., & Bonomo, R. A. (2010). Three decades of β-lactamase inhibitors. Clinical
Microbiology Reviews, 23(1), 160-201.
Duman, Y., Güçlüer, N., Serİndağ, A., & Tekerekoğlu, M. S. (2010). Antimicrobial susceptibility
of E. coli strains and presence of extended-spectrum beta lactamase. Firat Tip Dergisi, 15(4), 197200.
Fagan, M., Lindbæk, M., Grude, N., Reiso, H., Romøren, M., Skaare, D., & Berild, D. (2015).
Antibiotic resistance patterns of bacteria causing urinary tract infections in the elderly living in
nursing homes versus the elderly living at home: an observational study. BMC Geriatrics, 15(1),
98.
Farajnia, S., Alikhani, M. Y., Ghotaslou, R., Naghili, B., & Nakhlband, A. (2009). Causative
agents and antimicrobial susceptibilities of urinary tract infections in the northwest of Iran.
International Journal of Infectious Diseases, 13(2), 140-144.
Fasugba, O., Gardner, A., Mitchell, B. G., & Mnatzaganian, G. (2015). Ciprofloxacin resistance
in community-and hospital-acquired Escherichia coli urinary tract infections: A systematic review
and meta-analysis of observational studies. BMC Infectious Diseases, 15(1), 545.
Folgori, L., Bielicki, J., Heath, P. T., & Sharland, M. (2017). Antimicrobial-resistant Gramnegative infections in neonates: burden of disease and challenges in treatment. Current Opinion
in Infectious Diseases, 30(3), 281-288.
Foxman, B. (2002). Epidemiology of urinary tract infections: incidence, morbidity, and economic
costs. The American Journal of Medicine, 113(1), 5-13.
Foxman, B. (2010). The epidemiology of urinary tract infection. Nature Reviews Urology, 7(12),
653.
Frère, J. M., & Rigali, S. (2016). The alarming increase in antibiotic-resistant bacteria. Drug
Targets Rev, 3, 26-30.
Fünfstück, R., Nicolle, L. E., Hanefeld, M., & Naber, K. G. (2012). Urinary tract infection in
patients with diabetes mellitus. Clinical Nephrology, 77(1), 40.
Gbinigie, O. A., Ordóñez-Mena, J. M., Fanshawe, T. R., Plüddemann, A., & Heneghan, C. (2018).
Diagnostic value of symptoms and signs for identifying urinary tract infection in older adult
outpatients: systematic review and meta-analysis. Journal of Infection, 77(5), 379-390.
Ghanbari, F., Khademi, F., Saberianpour, S., Shahin, M., Ghanbari, N., Naderi, K., & MotalebiRad, T. (2017). An epidemiological study on the prevalence and antibiotic resistance patterns of
bacteria isolated from urinary tract infections in central Iran. Strategies, 4(7), 12.
Gupta, K., Hooton, T. M., & Stamm, W. E. (2001). Increasing antimicrobial resistance and the
management of uncomplicated community-acquired urinary tract infections. Annals of Internal
Medicine, 135(1), 41-50.
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., & Soper, D. E. (2011).
International clinical practice guidelines for the treatment of acute uncomplicated cystitis and
pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the

https://digitalcommons.bau.edu.lb/hwbjournal/vol3/iss1/5

12

Darwich et al.: SURVEILLANCE OF MULTIDRUG-RESISTANT UROPATHOGENIC ESCHERICHIA COL

−

−
−
−
−

−
−
−

−
−
−

−

−
−
−
−
−

European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases, 52(5),
e103-e120..
Hoban, D. J., Lascols, C., Nicolle, L. E., Badal, R., Bouchillon, S., Hackel, M., & Hawser, S.
(2012). Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization
of extended-spectrum beta-lactamase–producing species, in urinary tract isolates from
hospitalized patients in North America and Europe: results from the SMART study 2009–2010.
Diagnostic Microbiology and Infectious Disease, 74(1), 62-67.
Ibrahim, M. E., Bilal, N. E., & Hamid, M. E. (2012). Increased multi-drug resistant Escherichia
coli from hospitals in Khartoum state, Sudan. African Health Sciences, 12(3), 368-375.
Kaarme, J., Riedel, H., Schaal, W., Yin, H., Nevéus, T., & Melhus, Å. (2018). Rapid increase in
carriage rates of Enterobacteriaceae producing extended-spectrum β-lactamases in healthy
preschool children, Sweden. Emerging Infectious Diseases, 24(10), 1874.
Linhares, I., Raposo, T., Rodrigues, A., & Almeida, A. (2013). Frequency and antimicrobial
resistance patterns of bacteria implicated in community urinary tract infections: A ten-year
surveillance study (2000–2009). BMC Infectious Diseases, 13(1), 19.
Lob, S. H., Nicolle, L. E., Hoban, D. J., Kazmierczak, K. M., Badal, R. E., & Sahm, D. F. (2016).
Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada
and the United States, SMART 2010–2014. Diagnostic Microbiology and Infectious Disease,
85(4), 459-465.
Mahesh, E., Ramesh, D., Indumathi, V. A., Punith, K., Kirthi, R., & Anupama, H. A. (2010).
Complicated urinary tract infection in a tertiary care center in South India. Al Ameen Journal of
Medical Sciences, 3(2), 120-127.
Nicolas-Chanoine, M. H., Bertrand, X., & Madec, J. Y. (2014). Escherichia coli ST131, an
intriguing clonal group. Clinical Microbiology Reviews, 27(3), 543-574.
Ochoa, S. A., Cruz-Córdova, A., Luna-Pineda, V. M., Reyes-Grajeda, J. P., Cázares-Domínguez,
V., Escalona, G., & Parra-Ortega, I. (2016). Multidrug-and extensively drug-resistant
uropathogenic Escherichia coli clinical strains: phylogenetic groups widely associated with
integrons maintain high genetic diversity. Frontiers in Microbiology, 7, 2042.
Olowe, O. A., Eniola, K. I. T., Olowe, R. A., & Olayemi, A. B. (2007). Starch paper technique is
easy to detect beta lactamase detection from cases of diarrheagenic Escherichia coli in Osogbo.
Life Sci J, 4.
Oteo, J., Pérez-Vázquez, M., & Campos, J. (2010). Extended-spectrum β-lactamase producing
Escherichia coli: changing epidemiology and clinical impact. Current Opinion in Infectious
Diseases, 23(4), 320-326.
Palacios-Ceña, D., Hernández-Barrera, V., Jiménez-Trujillo, I., Serrano-Urrea, R., Fernández-delas-Peñas, C., & Carrasco-Garrido, P. (2017). Time trends in antibiotic consumption in the elderly:
Ten-year follow-up of the Spanish National Health Survey and the European Health Interview
Survey for Spain (2003–2014). Plos one, 12(11), e0185869.
Paniagua-Contreras, G. L., Monroy-Pérez, E., Rodríguez-Moctezuma, J. R., Domínguez-Trejo, P.,
Vaca-Paniagua, F., & Vaca, S. (2017). Virulence factors, antibiotic resistance phenotypes and Oserogroups of Escherichia coli strains isolated from community-acquired urinary tract infection
patients in Mexico. Journal of Microbiology, Immunology and Infection, 50(4), 478-485.
Pitout, J. D., Laupland, K. B., Church, D. L., Menard, M. L., & Johnson, J. R. (2005). Virulence
factors of Escherichia coli isolates that produce CTX-M-type extended-spectrum β-lactamases.
Antimicrobial Agents and Chemotherapy, 49(11), 4667-4670.
Rahn, D. D. (2008). Urinary tract infections: contemporary management. Urol Nurs, 28(5), 333341.
Rodríguez-Baño, J., Alcalá, J. C., Cisneros, J. M., Grill, F., Oliver, A., Horcajada, J. P., & Esteve,
M. (2008). Community infections caused by extended-spectrum β-lactamase–producing
Escherichia coli. Archives of Internal Medicine, 168(17), 1897-1902.
Ronald, A. (2002). The etiology of urinary tract infection: traditional and emerging pathogens.
The American Journal of Medicine, 113(1), 14-19.
Sanchez, G. V., Adams, S. J., Baird, A. M., Master, R. N., Clark, R. B., & Bordon, J. M. (2013).
Escherichia coli antimicrobial resistance increased faster among geriatric outpatients compared
with adult outpatients in the USA, 2000–10. Journal of Antimicrobial Chemotherapy, 68(8), 18381841.

Published by Digital Commons @ BAU, 2020

13

BAU Journal - Health and Wellbeing, Vol. 3, Iss. 1 [2020], Art. 5

−

−
−

−

−
−
−

Smithson, A., Chico, C., Ramos, J., Netto, C., Sanchez, M., Ruiz, J., & Bastida, M. T. (2012).
Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from
males with community febrile urinary tract infection. European Journal of Clinical Microbiology
& Infectious Diseases, 31(4), 423-430.
Stamm, W. E., & Norrby, S. R. (2001). Urinary tract infections: disease panorama and challenges.
The Journal of Infectious Diseases, 183(1), 1-4.
Stewardson, A. J., Vervoort, J., Adriaenssens, N., Coenen, S., Godycki-Cwirko, M., Kowalczyk,
A., & Harbarth, S. (2018). Effect of outpatient antibiotics for urinary tract infections on
antimicrobial resistance among commensal Enterobacteriaceae: A multinational prospective
cohort study. Clinical Microbiology and Infection, 24(9), 972-979.
Tabasi, M., Karam, M. R. A., Habibi, M., Yekaninejad, M. S., & Bouzari, S. (2015). Phenotypic
assays to determine virulence factors of uropathogenic Escherichia coli (UPEC) isolates and their
correlation with antibiotic resistance pattern. Osong Public Health and Research Perspectives,
6(4), 261-268.
Tajbakhsh, E., Tajbakhsh, S., & Khamesipour, F. (2015). Isolation and molecular detection of
Gram negative bacteria causing urinary tract infection in patients referred to Shahrekord hospitals,
Iran. Iranian Red Crescent Medical Journal, 17(5).
Ulug, M., & Gul, I. (2012). Investigation of the Results of Urine Cultures and Approaches to
Empirical Antibiotic Treatment of Community-Acquired Urinary Tract Infections in Elderly
Patients. Klimik J, 25(2), 71-76.
Wagenlehner, F. M., Weidner, W., & Naber, K. G. (2007). Therapy for prostatitis, with emphasis
on bacterial prostatitis. Expert Opinion on Pharmacotherapy, 8(11), 1667-1674.

https://digitalcommons.bau.edu.lb/hwbjournal/vol3/iss1/5

14

